Ablynx raises EUR 74.2 million

Antibody company Ablynx N.V. (Euronext:ABLX) raised EUR 74.2 million ($82.5 million) through a private placement of 5.5 million shares at EUR 13.40. The price is a 6% discount to Ablynx' close of EUR 14.30 on Wednesday, before the deal was announced. JPMorgan, Jefferies and KBC Securities were underwriters.

Ablynx said it may use the cash to develop clinical programs caplacizumab ( ALX-0081/ALX-0681) and ALX-0171 for new indications. Both are Nanobodies, which are therapeutic proteins based on single-domain antibody fragments. ...